SERVİKAL SİTOLOJİSİ NORMAL OLUP,HPV 16 VE 18 GENOTİPİ DIŞI HPV ENFEKSİYONU BULUNAN HASTALARDAKİ KOLPOSKOPİ SONUÇLARI

Yıl 2018, Cilt: 21 Sayı: 1, 6 - 9, 06.12.2019

H.öztürk Şahin , Beril Gürlek , Halit Arslan

Öz

AMAÇ

Literatürdeki güncel gelişmeler ,normal sitolojide
bulunan HPV(Human Papilloma Virus) tip 16 ve 18  dışındaki
genotiplerde servikal intraepitelyal lezyon (SIL) görülme risk analizi  çalışmalarına önem kazandırmıştır.Bizde
çalışmamızda bu hasta grubunda yaptığımız kolposkopi eşliğindeki biopsi sonuçlarını
inceledik.

GEREÇ VE  YÖNTEM

Çalışmamıza , Mayıs 2016-2018  tarihleri arasında servikal sitolojisi normal
olup,tekli yada çoklu HPV enfeksiyonu bulunmasına göre kategorize edilen 16 ve
18 dışı yüksek riskli HPV (hr-HPV)pozitifliği bulunan  104 hasta dahil edildi. Tüm hastalardan  histolojik tanı için kolposkopi eşliğinde
biopsi alındı.Sitolojik inceleme Bethesta metodu ile klasifiye edilirken,HPV
DNA analizi Hybrid  Capture 2 yöntemi ile
yapıldı.

SONUÇLAR

104 hastamızın 59’unda (%56,7)displazi  saptanmazken,33’ünde (%31,7) CIN1,12’sinde
(%11,5) ≥CIN 2 saptandı.Çoklu HPV enfeksiyonunun  SIL riskini arttırmadığı görüldü.≥CIN 2
saptanan 12 vakamızın 8’i(%66,6) HPV 31 genotipindeydi.

TARTIŞMA

HPV genotiplerinin risk skorlama çalışmaları,normal
sitolojisi bulunan hastalarda doğrudan kolposkopiye  refere edilecek  hastaların triajını değiştirebilir.

Anahtar Kelimeler

16/18 DIŞI HPV, NORMAL SİTOLOJİ, KOLPOSKOPİ

Kaynakça

• 1. H. zur Hausen . Papillomaviruses and cancer: from basic studies to clinical application Nature Rev Cancer, 2 (2002), pp. 350-392
• 2. National Cancer Institute at the National Institutes of Health (2018): Cervical Cancer Screening. [https://www.cancer. gov/types/cervical/hp/cervical-screening pdq#link/_133_ toc].
• 3. Cuzick J, Clavel C, Petry KU, et al. Overview of the European andNorth American studies on HPV testing in primary cervical cancerscreening. Int J Cancer. 2006;119:1095–1101
• 4. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding humanpapillomavirus testing in secondary prevention of cervical cancer.Vaccine. 2012;30:F88–F99.
• 5. L.S. Massad, M.H. Einstein, W.K. Huh,et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors J. Low. Genit. Tract Dis., 17 (2013), pp. S1-s27
• 6. Franco E, Villa LL, Sobrinho JP, et al. Epidemiology of acquisitionand clearance of cervical human papillomavirus infect ion in womenfrom a high-risk area for cervical cancer. J Infect Dis. 1999; 180:1415–1423
• 7. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitmentfrom a randomized controlled trial comparing human papillomavirustesting alone with conventional cytology as the primary cervicalcancer screening test. J Natl Cancer Inst. 2008; 100:492–501.
• 8. Cox JT, Schiffman M, Solomon D. ASCUS-LSIL Triage Study (ALTS)Group. Prospective follow-up suggests similar risk of subsequentcervical intraepithelial neoplasia grade 2 or 3 among women withcervical intraepithelial neoplasia grade 1 or negative colposcopy anddirected biopsy. Am J Obstet Gynecol. 2003; 188:1406.
• 9. W.C. Reeves, L.A. Brinton, M. Garcia, M.M. Brenes Human papillomavirus infection and cervical cancer in Latin America N Engl J Med, 320 (22) (1989), pp. 1437-1441
• 10. F.X. Bosch, N. Munoz, S.D. Sanjose, et al .Risk factors for cervical cancer in Columbia and Spain Int J Cancer, 52 (1992), pp. 750-758
• 11. Eluf-Neto, M. Booth, N. Munoz,et al .Human papillomavirus and invasive cervical cancer in Brazil Br J Cancer, 69 (1994), pp. 114-119
• 12. M.T. Kouri, S. Morsberger, A. Carrillo,et al.HPV prevalence among Mexican women with neoplastic and normal cervices Gynaecol Oncol, 70 (1998), pp. 115-120
• 13. S. Chinchareon, R. Herrero, N. Munoz,et al.Risk factors for cervical cancer in Thailand: a case control study J Natl Cancer Inst, 90 (1) (1998), pp. 50-57
• 14. F.X. Bosch, N. Munoz, S.D. Sanjose Human papillomavirus and the other risk factors for cervical cancer Biomed Pharmacother, 51 (1997), pp. 268-275
• 15. W.K. Huh, K.A. Ault, D. Chelmow,et al.Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance J. Low. Genit. Tract Dis., 19 (2015), pp. 91-96
• 16. P.E. Castle, M.H. Stoler, T.C. Wright Jr., A. Sharma, T.L. Wright, C.M. Behrens Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study Lancet Oncol., 12 (2011), pp. 880-890
• 17. H.A. Katki, M. Schiffman, P.E. Castle,et al.Benchmarking CIN 3+ risk as the basis for incorporating HPV and pap cotesting into cervical screening and management guidelines J. Low. Genit. Tract Dis., 17 (2013), pp. S28-S35
• 18. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combi-nation with liquid-based cytology in primary cervical screening(ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10:672Y82
• 19. Castillo M, Astudillo A, Clavero O, et al (2016). Poor cervical cancer screening attendance and false negatives. A call for organized screening. PLoS One, 11, e0161403.
• 20. J. Berkhof, N.W. Bulkmans, M.C. Bleeker,et al.Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear Cancer Epidemiology, Biomarkers & Prevention: a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 15 (2006), pp. 1268-1273
• 21. S.K. Kjaer, K. Frederiksen, C. Munk, T. Iftner Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence J. Natl. Cancer Inst., 102 (2010), pp. 1478-1488
• 22. J. Monsonego, J.T. Cox, C. Behrens,et al.Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial Gynecol. Oncol., 137 (2015), pp. 47-54
• 23. M. Schiffman, R.D. Burk, S. Boyle,et al.A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results J. Clin. Microbiol., 53 (2015), pp. 52-59
• 24. M. Schiffman, N. Hyun, T.R. Raine-Bennett,et al.A cohort study of cervical screening using partial HPV typing and cytology triage Int. J. Cancer, 139 (2016), pp. 2606-2615
• 25. L.T. Thomsen, K. Frederiksen, C. Munk, J. Junge, T. Iftner, S.K. Kjaer Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology Int. J. Cancer, 137 (2015), pp. 193-203
• 26. C.M. Wheeler, W.C. Hunt, J. Cuzick, E. Langsfeld, M. Robertson, P.E. Castle The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: a population-based study of opportunistic cervical screening in the United States Int. J. Cancer, 135 (2014), pp. 624-634
• 27. Aydoğmuş H, Aydoğmuş S. Comparison of Colposcopic Biopsy Results of Patients Who have Cytomorphological Normal but HPV 16-18 or Other High-Risk HPV Subtypes Positive. Asian Pac J Cancer Prev. 2019 Feb 26;20(2):417-420. PubMed PMID:30803201.
• 28.Karaca İ,Öztürk M,Comba C, et al.İmmediate biopsy of cytology-negative and non-HPV-16/18 oncogenic types positive patients.Diagnostic Cytopathology.2018;46:326-330.
• 29. Stoler MH, Wright TC Jr, Parvu V, Yanson K, Cooper CK, Andrews J. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology. Gynecol Oncol. 2019 Apr;153(1):26-33. doi: 10.1016/j.ygyno.2018.12.024. Epub 2019 Jan 10. PubMed PMID: 30638767.